Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes

Diabetologia

Volumn 52, Issue 12, 2009, Pages 2522-2530

  Tolonen, N ^a   Forsblom, C ^a   Thorn, L ^a   Waden J ^a   Rosengard Barlund M ^a   Saraheimo, M ^a   Feodoroff, M ^a   Makinen V P ^a   Gordin, D ^a   Taskinen, M R ^a   Groop, P H ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Albumin excretion rate; Albuminuria; Apolipoprotein; Cholesterol; Diabetic nephropathy; Estimated GFR; Lipid profile; Renal disease; Triacylglycerol; Type 1 diabetes

Indexed keywords

APOLIPOPROTEIN A2; APOLIPOPROTEIN B; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGE OF ONSET; APOLIPOPROTEIN A-II; APOLIPOPROTEINS B; BLOOD PRESSURE; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TIME FACTORS; TRIGLYCERIDES;

EID: 70949093630     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-009-1541-2     Document Type: Article

References (40)

1. SP Laing AJ Swerdlow SD Slater, et al.. 1999 The British Diabetic Association cohort study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus Diabet Med 16 466 471 10.1046/j.1464-5491. 1999.00076.x 10391393
2. J Tuomilehto K Borch-Johnsen A Molarius, et al.. 1998 Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland Diabetologia 41 784 790 10.1007/s001250050988 9686919 (Pubitemid 28313711)
3. The Diabetes Control and Complications (DCCT) Research Group 1995 Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial Kidney Int 47 1703 1720 10.1038/ki.1995.236
4. HH Parving E Hommel 1989 Prognosis in diabetic nephropathy BMJ 299 230 233 10.1136/bmj.299.6693.230 2504376
5. AR Andersen JS Christiansen JK Andersen S Kreiner T Deckert 1983 Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study Diabetologia 25 496 501 10.1007/BF00284458 6363177
6. PT Sawicki U Didjurgeit I Muhlhauser R Bender L Heinemann M Berger 1994 Smoking is associated with progression of diabetic nephropathy Diabetes Care 17 126 131 10.2337/diacare.17.2.126 8137682
7. H Mulec SA Johnsen O Wiklund S Bjorck 1993 Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 22 196 201 8322783
8. N Tolonen C Forsblom L Thorn FinnDiane Study Group, et al.. 2008 Relationship between lipid profiles and kidney function in patients with type 1 diabetes Diabetologia 51 12 20 10.1007/s00125-007-0858-y 17994214 (Pubitemid 50002203)
9. PH Groop T Elliott A Ekstrand, et al.. 1996 Multiple lipoprotein abnormalities in type I diabetic patients with renal disease Diabetes 45 974 979 10.2337/diabetes.45.7.974 8666151
10. MC Thomas M Rosengard-Barlund V Mills, et al.. 2006 Serum lipids and the progression of nephropathy in type 1 diabetes Diabetes Care 29 317 322 10.2337/diacare.29.02.06.dc05-0809 16443880
11. S Hadjadj B Duly-Bouhanick A Bekherraz, et al.. 2004 Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes Diabetes Metab 30 43 51 10.1016/S1262-3636(07)70088-5 15029097
12. J Shepherd JJ Kastelein V Bittner Treating to New Targets, Investigators, et al.. 2007 Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The treating to new targets (TNT) study Clin J Am Soc Nephrol 2 1131 1139 10.2215/CJN.04371206 17942759
13. J Atthobari AH Brantsma RT Gansevoort PREVEND Study Group, et al.. 2006 The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study Nephrol Dial Transplant 21 3106 3114 10.1093/ndt/gfl244 16720593 (Pubitemid 44567081)
14. S Sandhu N Wiebe LF Fried M Tonelli 2006 Statins for improving renal outcomes: a meta-analysis J Am Soc Nephrol 17 2006 2016 10.1681/ASN.2006010012 16762986 (Pubitemid 44036185)
15. BA Coonrod D Ellis DJ Becker, et al.. 1993 Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study Diabetes Care 16 1376 1383 10.2337/diacare.16.10.1376 8269796
16. N Chaturvedi S Bandinelli R Mangili G Penno RE Rottiers JH Fuller 2001 Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold Kidney Int 60 219 227 10.1046/j.1523-1755.2001.00789.x 11422754 (Pubitemid 32587557)
17. F Giorgino L Laviola P Cavallo Perin B Solnica J Fuller N Chaturvedi 2004 Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study Diabetologia 47 1020 1028 10.1007/s00125-004-1413-8 15170497 (Pubitemid 38918161)
18. AS Levey JP Bosch JB Lewis T Greene N Rogers D Roth 1999 A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group Ann Intern Med 130 461 470 10075613
19. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 10.1159/000180580 1244564
20. RW James D Pometta 1990 Immunofractionation of high density lipoprotein subclasses 2 and 3 similarities and differences of fractions isolated from male and female populations Atherosclerosis 83 35 45 10.1016/0021-9150(90)90128-6 2117929 (Pubitemid 20210743)
21. PM Sweetnam CH Bolton LG Downs, et al.. 2000 Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: The Caerphilly Study Eur J Clin Invest 30 947 956 10.1046/j.1365-2362.2000.00725.x 11114956
22. T O'Brien TT Nguyen BJ Hallaway, et al.. 1995 The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease Arterioscler Thromb Vasc Biol 15 228 231 7749830
23. RS Birjmohun GM Dallinga-Thie JA Kuivenhoven, et al.. 2007 Apolipoprotein A-II is inversely associated with risk of future coronary artery disease Circulation 116 2029 2035 10.1161/CIRCULATIONAHA.107.704031 17923573 (Pubitemid 350023748)
24. PJ Barter KA Rye 1996 High density lipoproteins and coronary heart disease Atherosclerosis 121 1 12 10.1016/0021-9150(95)05675-0 8678914 (Pubitemid 26072699)
25. P Alaupovic WJ Mack C Knight-Gibson HN Hodis 1997 The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial Arterioscler Thromb Vasc Biol 17 715 722 9108785
26. PH Groop MC Thomas M Rosengard-Barlund, et al.. 2007 HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes Diabetes Care 30 2706 2707 10.2337/dc07-0030 17620444 (Pubitemid 47547824)
27. GJ Hopkins PJ Barter 1986 Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins J Lipid Res 27 1265 1277 3559390
28. TJ Orchard YF Chang RE Ferrell N Petro DE Ellis 2002 Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study Kidney Int 62 963 970 10.1046/j.1523-1755.2002.00507.x 12164879 (Pubitemid 35316726)
29. LM Thorn C Forsblom J Waden on behalf of the FinnDiane Study Group, et al.. 2009 he metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes Diabetes Care 32 950 952 10.2337/dc08-2022 19196885
30. HM Colhoun ET Lee PH Bennett, et al.. 2001 Risk factors for renal failure: the WHO multinational study of vascular disease in diabetes Diabetologia 44 S46 S53 10.1007/PL00002939 11587050
31. AD Sniderman T Pedersen J Kjekshus, et al.. 1997 Putting low-density lipoproteins at center stage in atherogenesis Am J Cardiol 79 64 67 10.1016/S0002-9149(96)00677-7 9024738
32. PN Durrington CH Bolton M Hartog, et al.. 1978 Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia Clin Chim Acta 82 151 160 10.1016/0009-8981(78)90038-4 201398
33. HT Westerveld JE van Lennep HW van Lennep, et al.. 1998 Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography Arterioscler Thromb Vasc Biol 18 1101 1107 9672070
34. AA Yishak T Costacou G Virella, et al.. 2006 Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh epidemiology of diabetes complications cohort Nephrol Dial Transplant 21 93 100 10.1093/ndt/gfi103 16144851 (Pubitemid 43064805)
35. DCCT Research Group 1992 Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience Diabetes Care 15 886 894 10.2337/diacare.15.7.886
36. IH de Boer BC Astor H Kramer, et al.. 2008 Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis Clin J Am Soc Nephrol 3 125 132 10.2215/CJN.03390807 18057305
37. MR Taskinen 2005 Type 2 diabetes as a lipid disorder Curr Mol Med 5 297 308 10.2174/1566524053766086 15892649 (Pubitemid 40663135)
38. J Niemi V-P Mäkinen J Heikkonen, et al.. 2009 Estimation of VLDL, IDL, LDL, HDL(2), apoA-I and apoB from the Fiedewald inputs-apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes Ann Med 10.1080/07853890902893392 19412820
39. M Miller HN Ginsberg EJ Schaefer 2008 Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease Am J Cardiol 101 1003 1008 10.1016/j.amjcard.2007.11.046 18359322
40. JJ Kastelein WA van der Steeg I Holme TNT Study Group, IDEAL Study Group, et al.. 2008 Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 3002 3009 10.1161/CIRCULATIONAHA.107.713438 18519851